Literature DB >> 30361155

Pre-implantation Genetic Diagnosis: The Road Forward in Canada.

Vardit Ravitsky1, Minh Thu Nguyen2, Stanislav Birko3, Erika Kleiderman2, Anne Marie Laberge3, Bartha Maria Knoppers2.   

Abstract

The use of pre-implantation genetic diagnosis (PGD) is increasing as the list of indications it can test for constantly expands. This raises new challenges for clinicians and prospective parents regarding possible uses and calls for guidance. Policy approaches towards PGD vary greatly worldwide. The 2004 Canadian Assisted Human Reproduction Act does not provide guidance, except for prohibiting non-medical sex selection. Criminal legislation is an unsuitable policy instrument to regulate human genetics and reproductive medicine. We call for professional societies to issue guidelines regarding the uses of PGD that would establish the standard of care and legal norms. Such guidelines should be based on a patient-centered approach and respect individual autonomy in reproductive decision-making. Canadian approaches to PGD should also consider issues related to equity of access. Moreover, since PGD often raises concerns about eugenic uses, guidelines should also consider its societal impact and its implementation should be accompanied by policies that maintain or increase social support for people with disabilities. Finally, public engagement could provide an evidence-base regarding Canadian societal values and concerns that should guide regulatory reform, for example, the regulation of non-medical sex selection through PGD.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PGD; access; autonomy; guidelines; patient-centred care; regulation

Mesh:

Year:  2018        PMID: 30361155     DOI: 10.1016/j.jogc.2018.08.001

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  1 in total

1.  The 'serious' factor in germline modification.

Authors:  Erika Kleiderman; Vardit Ravitsky; Bartha Maria Knoppers
Journal:  J Med Ethics       Date:  2019-07-20       Impact factor: 2.903

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.